Turkish version of the Drug Hypersensitivity Quality of Life Questionnaire: assessment of reliability and validity

Basit Öğe Kaydı
dc.contributor.authorBavbek, Sevim
dc.contributor.authorOzdemir, Secil Kepil
dc.contributor.authorErdogan, Beyza Doganay
dc.contributor.authorKaraboga, Isil
dc.contributor.authorBuyukozturk, Suna
dc.contributor.authorGelincik, Asli
dc.contributor.authorYilmaz, Insu
dc.contributor.authorGoksel, Ozlem
dc.contributor.authorDursun, Adile Berna
dc.contributor.authorKarakaya, Gul
dc.contributor.authorKalyoncu, Ali Fuat
dc.contributor.authorOzseker, Ferhan
dc.contributor.authorKarakis, Gulden Pasaoglu
dc.contributor.authorErkekol, Ferda Oner
dc.contributor.authorKoycu, Gozde
dc.contributor.authorKeren, Metin
dc.contributor.authorBaiardini, Ilaria
dc.contributor.authorRomano, Antonino
dc.date.accessioned2019-10-27T22:58:46Z
dc.date.available2019-10-27T22:58:46Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractThe first disease-specific quality-of-life questionnaire in patients with drug hypersensitivity, Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q), was developed and validated recently. The aim of this study was to assess validity, reliability and responsiveness to interventions of the Turkish version of the DrHy-Q. The Turkish version of the DrHy-Q was administered to prospectively enrolled 736 patients with drug hypersensitivity from ten allergy units. To assess validity, all patients completed the validated Turkish version of Psychological General Well-Being Index (PGWBI). For test-retest reliability, 182 patients completed the DrHy-Q 1 week after the first questionnaire administration without any intervention. Responsiveness was assessed on 97 patients who had a DrHy-Q recorded at a follow-up visit after the intervention. The internal consistency and test-retest reliability of the scale were adequate (Cronbach's alpha = 0.934, intra-class correlation coefficient = 0.783). The DrHy-Q scores showed weak negative correlations with the PGWBI total and domain scores (r = - 0.378 to -0.254, p < 0.001). DrHy-Q was able to discriminate the patients with one drug hypersensitivity reaction from the patients with two and above two reactions (p = 0.012 and p < 0.001, respectively), and the patients who experienced a respiratory reaction from the patients who did not (p = 0.018). However, it did not discriminate the patients with comorbid disease including psychiatric comorbidity (p > 0.05). The baseline DrHy-Q scores were significantly higher than the post-intervention scores (p = 0.008). The Turkish version of DrHy-Q is reliable and valid for evaluating quality of life in patients with drug hypersensitivity, and it appeared responsive to interventions.en_US
dc.identifier.doi10.1007/s11136-015-1051-2en_US
dc.identifier.endpage109en_US
dc.identifier.issn0962-9343
dc.identifier.issn1573-2649
dc.identifier.issue1en_US
dc.identifier.pmid26091583en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage101en_US
dc.identifier.urihttps://doi.org/10.1007/s11136-015-1051-2
dc.identifier.urihttps://hdl.handle.net/11454/51639
dc.identifier.volume25en_US
dc.identifier.wosWOS:000367896300011en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofQuality of Life Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDisease-specific questionnairesen_US
dc.subjectDrug allergyen_US
dc.subjectDrug hypersensitivityen_US
dc.subjectQuality of lifeen_US
dc.titleTurkish version of the Drug Hypersensitivity Quality of Life Questionnaire: assessment of reliability and validityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu